Hyatt Regency Monterey Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2017



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Bile Acid Receptors as Signal Integrators in Liver and Metabolism (C1)


Organizer(s) Luciano Adorini, Kristina Schoonjans and Scott L. Friedman
March 3—7, 2017
Hyatt Regency Monterey • Monterey, California USA
Discounted Abstract Deadline: Nov 1, 2016
Abstract Deadline: Dec 5, 2016
Scholarship Deadline: Nov 1, 2016
Discounted Registration Deadline: Jan 9, 2017

Sponsored by Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Novo Nordisk A/S and Takeda Pharmaceutical Company Limited

Summary of Meeting:
In the last decade, bile acids have enjoyed a real renaissance, sparked by the identification at the turn of the millennium of their dedicated receptors, FXR and TGR5. This has been instrumental in revealing the key role bile acids play in regulating liver and metabolic homeostasis, transforming them from detergents facilitating the intestinal absorption of nutrients into versatile hormones. Signaling through FXR and TGR5 indeed modulates several metabolic pathways, regulating not only bile acid synthesis and enterohepatic recirculation, but also lipid, glucose and energy homeostasis. In addition, FXR and TGR5 agonists display anti-inflammatory and anti-fibrotic properties, making these agents interesting candidates for the treatment of several liver and metabolic diseases, including nonalcoholic steatohepatitis (NASH). With the hepatitis C virus infection nearly solved, NASH is already a medical problem of epidemic proportions poised to become by 2020 the leading indication for liver transplantation in the US. This conference will review genetics, structure and functions of bile acid receptors and will explore the intricate interactions among gut microbiota, bile acids and liver disease, as well as the multiple bidirectional signals along the gut-liver axis. Intriguingly, FXR agonists, like the bile acid derivative obeticholic acid, could have a beneficial role in the treatment of NASH by decreasing hepatic lipogenesis, steatosis and insulin resistance, while also inhibiting inflammatory and fibrogenic responses able to promote liver cirrhosis and hepatocellular carcinoma. The conference therefore aims at integrating basic, translational and clinical aspects of bile acid receptors, bringing together an interdisciplinary group of scientists to discuss the state of the art and propose new avenues of investigation in this active and dynamic field.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 24 hr (international) time


The meeting will begin on Friday, March 3 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Tuesday, March 7 with a closing plenary session from 17:00 to 19:15, followed by a social hour and entertainment. We recommend return travel on Wednesday, March 8 in order to fully experience the meeting.

FRIDAY, MARCH 3

4:00—8:00 PM
Arrival and Registration

Regency Foyer Terrace
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Regency Foyer Terrace

SATURDAY, MARCH 4

7:30—8:30 AM
Breakfast

Regency IV-VI
8:00—8:30 AM
Poster Setup

Regency IV-VI
8:30 AM—5:00 PM
Poster Viewing

Regency IV-VI
8:30—9:30 AM
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Regency Main I-III
* Luciano Adorini, Intercept Pharmaceuticals, Inc., Italy

Johan Auwerx, Ecole Polytechnique Fédérale de Lausanne - EPFL, Switzerland
New Insights into the Genetics of Mitochondria and Liver Metabolism

9:30—11:45 AM
FXR and TGR5: Dedicated Bile Acid Sensors
Meeting has ended...abstracts no longer viewable online.

Regency Main I-III
* Luciano Adorini, Intercept Pharmaceuticals, Inc., Italy

Kristina Schoonjans, École Polytechnique Fédérale de Lausanne – EPFL, Switzerland
TGR5 Signaling and Control of Metabolism

Coffee Break

David J. Mangelsdorf, University of Texas Southwestern Medical Center, USA
Dissecting the Tissue-Specific Actions of Endocrine FGF Signaling

Ronald M. Evans, Howard Hughes Medical Institute, Salk Institute, USA
Gut Feelings: Control of Fatty Acid and Cholesterol Metabolism by Intestinal FXR

Saskia van Mil, UMC Utrecht, Netherlands
Short Talk: FXR as a Homeostat of Amino Acid Breakdown and Ureagenesis

11:45 AM—12:45 PM
Lunch

Regency IV-VI
12:00—2:30 PM
Poster Session 1

Regency IV-VI
2:30—4:30 PM
Workshop 1: Bile Acid Receptors in Health and Disease

Regency Main I-III
* Antonio Moschetta, Clinica Medica Frugoni, University of Bari, Italy

Jan Freark de Boer, University Medical Center Groningen, Netherlands
Intestinal FXR Controls Transintestinal Cholesterol Excretion in Mice

Hanns-Ulrich Marschall, Sahlgrenska Academy, University of Gothenburg, Sweden
Decreased Intestinal Glucose Absorption in Healthy Volunteers Treated with the FXR Agonist Obeticholic Acid

Richard Appleby, Imperial College, UK
A DIET1 Single Nucleotide Polymorphism (SNP) is Associated with Lower Fibroblast Growth Factor 19 (FGF19) and Serum Triglycerides (TG) in a Population of Non-Alcoholic Fatty Liver Disease (NAFLD)

Sayeepriyadarshini Anakk, University of Illinois at Urbana-Champaign, USA
Bile Acids - A Metabolite that Channels the Gender Gap in Hepatocellular Carcinoma

Raffaella M. Gadaleta, University of Bari, Italy
A Non-Tumorigenic FGF19 Analogue Protects Mice from Spontaneous Hepatocarcinogenesis

Mélanie Verreault, Laval University, Canada
FXR Agonists Inhibit Prostate Cancer Cell Proliferation Through AR-Dependent and –Independent Mechanisms

Karolina Emilia Zaborska, Cornell University, USA
TGR5 Contributes to Arterial Blood Pressure (AP) Lowering after Vertical Sleeve Gastrectomy in Mice

Moreshwar S. Desai, Baylor College of Medicine, USA
TGR5 Modulates Myocardial Adaptation to Stress

4:30—5:00 PM
Coffee Available

Regency Foyer Terrace
5:00—7:00 PM
Genetics and Epigenetics of Bile Acid Receptors
Meeting has ended...abstracts no longer viewable online.

Regency Main I-III
* Jelena Mann, Newcastle University, UK

David D. Moore, Baylor College of Medicine, USA
FXR Mutations Induce Cholestasis

Elizabeth K. Speliotes, University of Michigan, USA
Gene Set Enrichment Based on Human Genome-Wide Association Study Data Implicates FXR/RXR Activation as a Common Pathway Affecting Blood Lipids Levels and Nonalcoholic Fatty Liver Disease

Kim Jongsook Kemper, University of Illinois at Urbana-Champaign, USA
FGF15 Signal-Induced Phosphorylation of FXR in Bile Acid Regulation and Signal Termination

Andres Acosta, Mayo Clinic, USA
Short Talk: Obesity a State of Bile Acid Pathway Deficiency: Association of serum FGF-19, and GPBAR1 and NR1H4 Gene Variant with Gastrointestinal Traits, Body Weight and BMI in Obesity

7:00 PM
On Own for Dinner


SUNDAY, MARCH 5

7:30—8:30 AM
Breakfast

Regency IV-VI
8:30—11:30 AM
Interplay Between Bile Acids and the Gut Microbiome
Meeting has ended...abstracts no longer viewable online.

Regency Main I-III
* Steven A. Kliewer, University of Texas Southwestern Medical Center, USA

Richard A. Flavell, HHMI, Yale University School of Medicine, USA
Role of the Intestinal Microbiome in Liver Disease

Fredrik Bäckhed, University of Gothenburg, Sweden
Functional Interactions between Gut Microbiota, Bile Acids and Host Metabolism

Coffee Break

Frank J. Gonzalez, National Institutes of Health, USA
Gut Microbiota, Bile Acids, FXR and Metabolic Disease

Gary D. Wu, University of Pennsylvania School of Medicine, USA
Modulation of Gut Microbiota by the Bile Acid Derivative Obeticholic Acid

Sander Kersten, Wageningen University, Netherlands
Short Talk: Gut Microbiota Impacts Non-Alcoholic Fatty Liver Disease via Bile Acids

11:30 AM—5:00 PM
On Own for Lunch

11:30 AM—1:00 PM
Poster Setup

Regency IV-VI
1:00—10:00 PM
Poster Viewing

Regency IV-VI
4:30—5:00 PM
Coffee Available

Regency Foyer Terrace
5:00—7:00 PM
Gut-Liver Metabolic Axis
Meeting has ended...abstracts no longer viewable online.

Regency Main I-III
* Kristina Schoonjans, École Polytechnique Fédérale de Lausanne – EPFL, Switzerland

Frank Reimann, University of Cambridge, UK
Molecular Mechanisms in Bile Acid-Stimulated GLP-1 Secretion

Steven A. Kliewer, University of Texas Southwestern Medical Center, USA
Tissue-Specific Actions of Metabolic Hormones FGF15/19 and FGF21

Antonio Moschetta, Clinica Medica Frugoni, University of Bari, Italy
Gut-Liver Axis in the Control of Cholestasis and HCC Development

Catherine Williamson, King's College London, UK
Short Talk: Bile Acid Supplementation Alters the Gut Microbiome, Metabolome and Metagenome to Mimic the Intestinal Environment of Pregnancy

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Regency IV-VI
7:30—10:00 PM
Poster Session 2

Regency IV-VI

MONDAY, MARCH 6

7:30—8:30 AM
Breakfast

Regency IV-VI
8:30—11:30 AM
Pathways to NASH, Liver Cirrhosis, and HCC
Meeting has ended...abstracts no longer viewable online.

Regency Main I-III
* Michael Trauner, Medical University of Vienna, Austria

Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA
Metabolic Dysregulation and Inflammation in the Pathogenesis of NASH, Hepatic Fibrosis and HCC

Jelena Mann, Newcastle University, UK
Epigenetic Regulation in Liver Fibrosis

Coffee Break

Li Wang, University of Connecticut, USA
Nuclear Receptor and lncRNA Crosstalk in Cholestatic Liver Injury

Yujin Hoshida, Icahn School of Medicine at Mount Sinai, USA
Genetic and Genomic Features of Fatty Liver Disease, Fibrosis and Cancer

Loning Fu, Baylor College of Medicine, USA
Short Talk: Circadian Dysfunction in Bile Acid Metabolism Promotes NAFLD-induced Hepatocarcinogenesis

11:30 AM—5:00 PM
On Own for Lunch

11:30 AM—1:00 PM
Poster Setup

Regency IV-VI
1:00—10:00 PM
Poster Viewing

Regency IV-VI
4:30—5:00 PM
Coffee Available

Regency Foyer Terrace
5:00—7:00 PM
Metabolic Inflammation and NASH
Meeting has ended...abstracts no longer viewable online.

Regency Main I-III
* David J. Mangelsdorf, University of Texas Southwestern Medical Center, USA

Gökhan S. Hotamisligil, Harvard University, USA
Immunometabolic Regulation of Liver Lipid Homeostasis

Catherine Postic, Institut Cochin, France
Hepatokines in Metabolic Diseases: New Insights into FGF21 Regulation by Glucose

Gyongyi Szabo, University of Massachusetts Medical School, USA
Immune Cell and Hepatocyte Cross-Talk in NASH

Mark S. Sundrud, The Scripps Research Institute, USA
Short Talk: The Xenobiotic Transporter Mdr1 Permits T Cell Adaptation to Mucosa-Associated Bile Acids in the Ileum

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Regency IV-VI
7:30—10:00 PM
Poster Session 3

Regency IV-VI

TUESDAY, MARCH 7

7:30—8:30 AM
Breakfast

Regency IV-VI
8:30—11:30 AM
Targeting Bile Acid Receptors in Liver and Metabolic Diseases
Meeting has ended...abstracts no longer viewable online.

Regency Main I-III
* Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA

Michael Trauner, Medical University of Vienna, Austria
FXR Targeting in Cholestatic and Metabolic Liver Diseases

Verena Simone Keitel, University Hospital Duesseldorf, Germany
TGR5 in Liver Diseases

Coffee Break

Bart Staels, Institut Pasteur de Lille, Université Lille, France
Nuclear Receptor Signaling in the Treatment of Liver and Metabolic Disorders

Luciano Adorini, Intercept Pharmaceuticals, Inc., Italy
Treatment of Liver and Metabolic Diseases by the FXR Agonist Obeticholic Acid: Preclinical Profile

Karim Christian El Kasmi, University of Colorado Denver, USA
Short Talk: Intravenous FXR Agonist GW4064 Prevents Parenteral Nutrition Associated Cholestasis (PNAC) in Mice

11:30 AM—5:00 PM
On Own for Lunch

2:30—4:30 PM
Workshop 2: Approaches to NASH Treatment

Regency Main I-III
* Bart Staels, Institut Pasteur de Lille, Université Lille, France

Pooja Jha, École Polytechnique Fédérale de Lausanne, Switzerland
Identification of Lipid Biomarkers of NAFLD using a Systems Genetics Approach

Barbara C. Hansen, University of South Florida, Tampa, USA
Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Nonhuman Primates (NHP’s) is Comparable to Humans for Metabolic Features, Histology and Imaging

Rui Eduardo Castro, Associacao FFUL Investigação Desenvolvimento FARM-ID, Portugal
miR-21 Ablation and Obeticholic Acid Ameliorate NASH in Mice

Moshe Levi, University of Colorado Health Sciences Center, USA
The FXR/TGR5 Dual Agonist INT-767 Prevents and Reverses Western Diet-Induced NASH and Modulates Major Lipid Metabolic Pathways in Mic

Jonathan Roth, Intercept Pharmaceuticals, Inc., USA
Comparative Efficacy of INT-767 vs Liraglutide in Gubra AMLN Mice

Yusuke Sasaki, University of Tokyo, Japan
K-877 Prevents F4/80 Positive Cell Accumulation and Ballooning Degeneration in Non-Alcoholic Steatohepatitis (NASH) Model Mice

Andrew Billin, Gilead Sciences, USA
Pharmacodynamic Effects of the Oral, Non-Steroidal Farnesoid X Receptor Agonist Gs-9674 in Healthy Volunteers

4:30—5:00 PM
Coffee Available

Regency Foyer Terrace
5:00—7:00 PM
NASH Therapeutics
Meeting has ended...abstracts no longer viewable online.

Regency Main I-III
* Michael Trauner, Medical University of Vienna, Austria

Claus M. Kremoser, Phenex AG, Germany
Non-Steroidal FXR Agonists in the Treatment of NASH and Other Liver Diseases

David Shapiro, Intercept Pharmaceuticals, Inc., USA
Obeticholic Acid in the Treatment of NASH and Other Chronic Liver Diseases

Julian R.F. Walters, Imperial College London, UK
Short Talk: Beyond NASH and Liver Disease: Treatment of Bile Acid Diarrhea by Obeticholic Acid

7:00—7:15 PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Regency Main I-III
7:15—8:15 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Regency IV-VI
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources. Novo Nordisk A/S funding is not being used for this function.

Regency IV-VI

WEDNESDAY, MARCH 8

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Gilead Sciences, Inc. Intercept Pharmaceuticals, Inc.
Novo Nordisk A/S Takeda Pharmaceutical Company Limited

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:

ALPCO

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13DK112338-01

"Funding for this conference was made possible (in part) by DK112338-01 from NIH. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government."


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Genmab A/S


Intercept Pharmaceuticals, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676